New OTC product with unique technology to help allergy sufferers
![](/46/pdcnewsitem/04/48/49/GSK.png)
GSK launches Flonase Sensimist allergy relief nationwide.
GSK Consumer Healthcare has launched Flonase Sensimist Allergy Relief (fluticasone furoate, 27.5 mcg spray), a new over-the-counter (OTC) treatment for symptoms associated with seasonal and perennial allergies.
With unique MistPro technology, Flonase Sensimist delivers a fine, gentle, yet powerful mist spray, providing non-drowsy, 24-hour relief of allergy symptoms including itchy, watery eyes, nasal congestion, runny or itchy nose and sneezing.
Taken once daily, directly in the nose, the treatment protects against allergies caused by triggers including pollen, mold, dust and pets. Unlike most OTC allergy pills, which act on histamine alone, Flonase Sensimist helps block six key inflammatory substances; it has also been found to be 40% stronger than a leading non-drowsy allergy pill.
"For the more than 50 million Americans who suffer from allergies, the burden is more than just a stuffy nose," said Dr Clifford Bassett, Founder and Medical Director of Allergy & Asthma Care of New York. "Uncontrolled allergies have a measurable impact on quality of life, affecting children and adults. In my patient population, having a proactive treatment plan in place makes a big difference in managing their allergies."
Additional key features of Flonase Sensimist's unique, ergonomic design include
Previously available by prescription only, Flonase Sensimist was approved by FDA for OTC availability in August 2016. Sensimist joins Flonase Allergy Relief and Children's Flonase Allergy Relief in the Flonase product family, offering a comfortable spray experience so consumers can pick what they prefer.
"GSK Consumer Healthcare has a strong heritage in discovering and developing respiratory products to meet patient needs worldwide," said Jennifer Nadelson, Senior Brand Manager, Flonase. "With Flonase Sensimist, we're proud to offer allergy sufferers an additional product option providing more complete symptom reliefi in a new, unique, user-friendly device."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance